-

REMINDER – GitLab Inc. Shareholders - Robbins LLP Reminds Stockholders of the GTLB Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired GitLab Inc. (NASDAQ: GTLB) securities between June 6, 2023 and March 4, 2024. GitLab is a global software company that designs and develops software solutions.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that GitLab Inc. (GTLB) Misled Investors Regarding Demand for its Product

According to the complaint, during the class period, defendants created the false impression that they possessed reliable information pertaining to the Company’s ability to develop and incorporate AI throughout the software development cycle to optimize code generation thereby increasing market demand and making all levels of software development more affordable and properly monetizing its AI features. In truth, there was weak market demand for GitLab’s touted AI features and the Company was incurring an increasing amount of expenses involving JiHu, its joint venture in China, as well as the annual company-wide summit. Defendants misled investors by continually highlighting its AI-driven innovations to develop software more efficiently and drive market share demands.

Plaintiff alleges that on March 4, 2024, GitLab issued a press release reporting strong Q1 2024 results and then immediately followed this with a disclosure announcing lower than expected full-year guidance for 2025. GitLab attributed it to time needed to “build pipeline and close deals on new products.” On this news, the price of GitLab’s common stock declined from $74.47 per share on March 4, 2024, to $58.84 per share on March 5, 2024, a decline of about 21%.

What Now: You may be eligible to participate in the class action against GitLab Inc. Shareholders who want to serve as lead plaintiff for the class must submit their application to the court by November 4, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against GitLab Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:GTLB

Release Summary
Robbins LLP is Investigating Allegations that GitLab Inc. (GTLB) Misled Investors Regarding Demand for its Product
Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Investor Alert: Robbins LLP Informs Investors of the Corcept Therapeutics Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporation (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025. Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. For more information, submi...

ARDT Class Action Reminder: Stockholders Who Lost Money Investing in Ardent Health, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ardent Health, Inc. (NYSE: ARDT) securities between July 18, 2025 and November 12, 2025. Ardent Health and its affiliates operate acute care hospitals and other healthcare facilities. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What are the allegations? Robbins LLP is Investigating...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the NuScale Power Corporation Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired NuScale Power Corporation (NYSE: SMR) Class A shares between May 13, 2025 and November 6, 2025. NuScale is a nuclear technology company focused on scalable, modular reactors. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that...
Back to Newsroom